The warrant exercise provides minimal cash ($837K) while adding substantial future dilution (up to ~6.4M new shares via Series F/G warrants) contingent on shareholder approval of an authorized share increase. Combined with the Nasdaq bid-price deficiency notice from September 25, the company faces both near-term delisting risk and ongoing equity overhang. Monitor shareholder vote on authorized share increase and any reverse stock split plans to regain Nasdaq compliance.
Price Chart
Executive Summary
Silexion Therapeutics entered into definitive agreements for the immediate cash exercise of outstanding Series E warrants to purchase up to 3,216,928 ordinary shares at a reduced price of $0.2603 per share, raising gross proceeds of $837,366.36. The company will issue new Series F and Series G warrants as consideration, exercisable after shareholder approval of an authorized share increase. This offering provides near-term cash but creates significant future dilution overhang, and comes just days after a Nasdaq bid-price deficiency notice.
Key Financial Metrics
Key Facts
- Immediate exercise of Series E warrants for 3,216,928 ordinary shares at $0.2603/share, gross proceeds of $837,366.36
- Company will issue new unregistered Series F and Series G warrants, each for up to 3,216,928 ordinary shares, exercisable at $0.2603/share after shareholder approval of authorized share increase
- Exercise price for all outstanding Series E warrants (3,846,161 total) reduced to $0.2603/share
- Offering expected to close on or about September 29, 2026, with H.C. Wainwright & Co. as exclusive placement agent
- Nasdaq Staff letter received September 25, 2026, notifying company of bid price deficiency below $1.00 for 30 consecutive days
Financial Impact
Gross proceeds of $837,366.36 from warrant exercise; potential future dilution from up to 6,433,856 new ordinary shares issuable upon exercise of Series F and Series G warrants, plus existing Series E warrant overhang of 3,846,161 shares
Risk Factors
- Potential delisting if Nasdaq bid-price compliance not regained
- Significant future dilution from Series F and Series G warrants (up to 6,433,856 shares) upon authorized share increase
- Low gross proceeds ($837K) relative to dilution — capital raise is small and may not address cash runway needs
- Shareholder approval required for authorized share increase creates execution risk
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3370802 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1750 (−13.78%) |
Oct 5, 2026 21d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1750 (+33.41%) |
Sep 30, 2026 26d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1750 (−36.82%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1750 (+36.89%) |
Sep 29, 2026 27d ago | 8-K | $0.3180 | awaiting T+20 | — | $0.1750 (+44.97%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 | awaiting T+20 | — | $0.1750 (+45.04%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1750 (−29.55%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1750 (−29.55%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1750 (+29.55%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1750 (+58.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers